Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Baxter
Express Scripts
Harvard Business School

Last Updated: January 31, 2023

DETECTNET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Detectnet, and when can generic versions of Detectnet launch?

Detectnet is a drug marketed by Radiomedix and is included in one NDA. There are three patents protecting this drug.

This drug has eleven patent family members in six countries.

The generic ingredient in DETECTNET is copper cu-64 dotatate. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the copper cu-64 dotatate profile page.

DrugPatentWatch® Generic Entry Outlook for Detectnet

Detectnet will be eligible for patent challenges on September 3, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 3, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for DETECTNET
International Patents:11
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in DETECTNET?DETECTNET excipients list
DailyMed Link:DETECTNET at DailyMed
Drug patent expirations by year for DETECTNET
DrugPatentWatch® Estimated Generic Entry Opportunity Date for DETECTNET
Generic Entry Date for DETECTNET*:
Constraining patent/regulatory exclusivity:
FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for DETECTNET

US Patents and Regulatory Information for DETECTNET

DETECTNET is protected by three US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of DETECTNET is See Plans and Pricing.

This potential generic entry date is based on FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting DETECTNET

Pet tracer for imaging of neuroendocrine tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

PET tracer for imaging of neuroendocrine tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

PET tracer for imaging of neuroendocrine tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

FDA Regulatory Exclusivity protecting DETECTNET

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Radiomedix DETECTNET copper cu-64 dotatate SOLUTION;INTRAVENOUS 213227-001 Sep 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Radiomedix DETECTNET copper cu-64 dotatate SOLUTION;INTRAVENOUS 213227-001 Sep 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Radiomedix DETECTNET copper cu-64 dotatate SOLUTION;INTRAVENOUS 213227-001 Sep 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Radiomedix DETECTNET copper cu-64 dotatate SOLUTION;INTRAVENOUS 213227-001 Sep 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Radiomedix DETECTNET copper cu-64 dotatate SOLUTION;INTRAVENOUS 213227-001 Sep 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DETECTNET

See the table below for patents covering DETECTNET around the world.

Country Patent Number Title Estimated Expiration
Hungary E044625 See Plans and Pricing
European Patent Office 3536346 TRACEUR TEP POUR L'IMAGERIE DE TUMEURS NEURO-ENDOCRINES (PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS) See Plans and Pricing
Denmark 3536346 See Plans and Pricing
Spain 2842998 See Plans and Pricing
Spain 2732823 See Plans and Pricing
Poland 2750717 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2013029616 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
McKinsey
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.